

FORM 51-102F3

MATERIAL CHANGE REPORT

Item 1. Name and Address of Company

BioHarvest Sciences Inc. (the "Company")
Suite 1140 – 625 Howe Street
Vancouver, BC, V6C 2T6

Item 2. Date of Material Change

May 29, 2024 and June 3, 2024.

Item 3. News Release

The news releases (the "News Releases") were issued on May 29, 2024 and June 3, 2024 and disseminated by Stockwatch.

Item 4. Summary of Material Change

On May 29, 2024, the Company announced a consolidation (the "Consolidation") of all of its issued and outstanding common shares ("Common Shares") on the basis of thirty-five (35) pre-Consolidation Common Shares for every one (1) post-Consolidation Common Share

On June 3, 2024, the Company completed the Consolidation. The Common Shares began trading on a consolidated basis on the Canadian Securities Exchange on June 3, 2024.

Item 5. Full Description of Material Change

See the News Releases announcing the Consolidation and the completion of the Consolidation, attached hereto as Schedule "A".

Item 6. Reliance on Subsection 7.1(2) or (3) of National Instrument 51-102

Not applicable.

Item 7. Omitted Information

None.

Item 8. Executive Officer

David K. Ryan
Secretary and Director
(604) 622-1187

Item 9. Date of Report

June 3, 2024.

SCHEDULE "A"

NEWS RELEASES

(See attached)

BIOHARVEST SCIENCES INC. ANNOUNCES SHAREHOLDER APPROVAL OF SHARE CONSOLIDATION

VANCOUVER, CANADA, and REHOVOT, ISRAEL, May 29, 2024 – BioHarvest Sciences Inc. (“BioHarvest” or the “Company”) (CSE: BHSC) (OTCQB: CNVCF) (FSE: 8MV) announces that it plans to consolidate (the “Consolidation”) its issued and outstanding common shares (“Common Shares”) on the basis of thirty-five (35) pre-Consolidation Common Shares for every one (1) post-Consolidation Common Share.

Pursuant to Section 4.6(8) of Policy 4 of the Canadian Securities Exchange (the “CSE”), the shareholders of the Company (the “Shareholders”) approved the Consolidation at the annual general and special meeting of the Shareholders held on May 27, 2024.

There are currently 574,878,008 Common Shares issued and outstanding. Upon completion of the Consolidation, there is expected to be approximately 16,425,077 Common Shares issued and outstanding, subject to rounding of fractional Common Shares.

The Common Shares are expected to begin trading on a consolidated basis on the CSE on June 3, 2024. The record date for the Consolidation is June 3, 2024. The Consolidation is subject to approval by the CSE.

The new CUSIP number for the post-Consolidation Common Shares will be 09076J207 and the new ISIN will be CA09076J2074. The Common Shares will continue to trade on the CSE under the symbol "BHSC", and the Company's name will not change.

About BioHarvest Sciences Inc.

BioHarvest Sciences Inc. (CSE: BHSC) (OTCQB: CNVCF) (FSE: 8MV) is a leader in botanical synthesis, leveraging its patented technology process to grow the active ingredients in plants, without the need to grow the underlying plant. BioHarvest is leveraging its botanical synthesis technology to develop the next generation of science-based and clinically proven therapeutic solutions within two major business verticals; as a contract development and production organization (CDMO) on behalf of customers seeking complex molecules, and as a creator of proprietary nutraceutical health and wellness products, which includes dietary supplements. To learn more, please visit www.bioharvest.com.

Ilan Sobel
Chief Executive Officer

Corporate Contact:

Dave Ryan, VP Investor Relations & Director
Phone: 1 (604) 622 -1186
Email: info@bioharvest.com

Investor Relations Contact:

MZ Group - MZ North America
(949) 259-4987
BHSC@mzgroup.us

Forward-Looking Statements

Information set forth in this news release might include forward-looking statements that are based on management's current estimates, beliefs, intentions, and expectations, and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. There is no assurance of additional future contracts, and there is no assurance that signed agreements will progress past the first stage. Readers are cautioned that increased revenue is not necessarily an increase in net income or profitability as costs will likely increase as

well. All forward-looking statements are inherently uncertain and actual results may be affected by a number of material factors beyond our control. Readers should not place undue reliance on forward-looking statements. The Company does not intend to update forward-looking statement disclosures other than through our regular management discussion and analysis disclosures which can be found under the Company's profile on www.sedarplus.ca.

The Canadian Securities Exchange has neither approved nor disapproved the information contained herein and does not accept responsibility for the adequacy or accuracy of this news release.

To view the source version of this press release, please visit:



CSE: BHSC – FSE:8MV – OTC: CNVCF

BIOHARVEST SCIENCES INC. ANNOUNCES COMPLETION OF CONSOLIDATION

VANCOUVER, CANADA, and REHOVOT, ISRAEL, June 3, 2024 – BioHarvest Sciences Inc. (“BioHarvest” or the “Company”) (CSE: BHSC) (OTCQB: CNVCF) (FSE: 8MV) announces the completion of the consolidation (the “Consolidation”) of all of its issued and outstanding common shares (“Common Shares”) on the basis of thirty-five (35) pre-Consolidation Common Shares for every one (1) post-Consolidation Common Share.

Immediately upon completion of the Consolidation, there were 16,425,077 Common Shares issued and outstanding.

The Common Shares begin trading on a consolidated basis on the Canadian Securities Exchange (the “CSE”) on June 3, 2024.

The new CUSIP number for the post-Consolidation Common Shares is 09076J207 and the new ISIN is CA09076J2074. The Common Shares continue to trade on the CSE under the symbol "BHSC", and the Company's name did not change.

About BioHarvest Sciences Inc.

BioHarvest Sciences Inc. (CSE: BHSC) (OTCQB: CNVCF) (FSE: 8MV) is a leader in botanical synthesis, leveraging its patented technology process to grow the active ingredients in plants, without the need to grow the underlying plant. BioHarvest is leveraging its botanical synthesis technology to develop the next generation of science-based and clinically proven therapeutic solutions within two major business verticals; as a contract development and production organization (CDMO) on behalf of customers seeking complex molecules, and as a creator of proprietary nutraceutical health and wellness products, which includes dietary supplements. To learn more, please visit www.bioharvest.com.

Ilan Sobel
Chief Executive Officer

Corporate Contact:

Dave Ryan, VP Investor Relations & Director
Phone: 1 (604) 622 -1186
Email: info@bioharvest.com

Investor Relations Contact:

MZ Group - MZ North America
(949) 259-4987
BHSC@mzgroup.us

Forward-Looking Statements

Information set forth in this news release might include forward-looking statements that are based on management's current estimates, beliefs, intentions, and expectations, and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. There is no assurance of additional future contracts, and there is no assurance that signed agreements will progress past the first stage. Readers are cautioned that increased revenue is not necessarily an increase in net income or profitability as costs will likely increase as well. All forward-looking statements are inherently uncertain and actual results may be affected by a number of material factors beyond our control. Readers should not place undue reliance on forward-looking statements. The Company does not intend to update forward-looking statement disclosures other than through our regular management discussion and analysis disclosures which can be found under the Company's profile on www.sedarplus.ca.

The Canadian Securities Exchange has neither approved nor disapproved the information contained herein and does not accept responsibility for the adequacy or accuracy of this news release.